Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MYC Protein-positive Diffuse Large B-Cell Lymphoma Features an Activated B-Cell Receptor Signal Pathway.
|
28291124 |
2017 |
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma.
|
26927665 |
2016 |
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CD30 expression and its correlation with MYC rearrangement in de novo diffuse large B-cell lymphoma.
|
26340843 |
2016 |
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
It was verified in this patient population that the use of BCL2 and MYC immunohistochemistry, performed with available in vitro diagnostic-cleared antibodies, provides rapid prognostic information in patients with de novo diffuse large B-cell lymphoma.
|
26421520 |
2016 |
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Negative impact of concurrent overexpression of MYC and BCL2 in patients with advanced diffuse large B-cell lymphoma treated with dose-intensified immunochemotherapy.
|
27071312 |
2016 |
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
On average, 91 and 76% of neoplastic cells were positive for MYC expression in Burkitt lymphoma and double hit lymphoma, respectively, while only 20% neoplastic cells were positive for MYC expression in diffuse large B-cell lymphoma.
|
27282353 |
2016 |
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Neither BCL6 translocation alone (more frequent in activated B-cell like diffuse large B-cell lymphoma) nor in combination with MYC translocation (observed in 2.0% of diffuse large B-cell lymphoma) predicted poorer survival in diffuse large B-cell lymphoma patients.
|
26573234 |
2016 |
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B-cell lymphoma.
|
27027803 |
2016 |
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A strong host response and lack of MYC expression are characteristic for diffuse large B cell lymphoma transformed from nodular lymphocyte predominant Hodgkin lymphoma.
|
27708232 |
2016 |
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical and Pathologic Correlation of Increased MYC Gene Copy Number in Diffuse Large B-Cell Lymphoma.
|
27633159 |
2016 |
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Non-IGH gene was the preferential partner of rearrangement in those diffuse large B-cell lymphoma showing MYC heteroclonality (P=0.016) and/or non-classical FISH breakpoints (P=0.058).
|
27125356 |
2016 |
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.
|
27469075 |
2016 |
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Diffuse large B-cell lymphoma with MYC gene rearrangements: Current perspective on treatment of diffuse large B-cell lymphoma with MYC gene rearrangements; case series and review of the literature.
|
26820684 |
2016 |
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MYC cytogenetic status correlates with expression and has prognostic significance in patients with MYC/BCL2 protein double-positive diffuse large B-cell lymphoma.
|
25828389 |
2015 |
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome.
|
25827211 |
2015 |
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
|
26541272 |
2015 |
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma.
|
25741152 |
2015 |
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma.
|
26158410 |
2015 |
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma.
|
25284491 |
2015 |
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
miR expression in MYC-negative DLBCL/BL with partial trisomy 11 is similar to classical Burkitt lymphoma and different from diffuse large B-cell lymphoma.
|
25677902 |
2015 |
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
C-MYC aberrations as prognostic factors in diffuse large B-cell lymphoma: a meta-analysis of epidemiological studies.
|
24740248 |
2014 |
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
MYC gene alterations in diffuse large B-cell lymphomas and in B-cell lymphomas, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma are frequently associated with BCL2 or/and BCL6 translocations conferring a very aggressive behavior.
|
25696841 |
2014 |
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
p53 expression is a strong marker of inferior survival in de novo diffuse large B-cell lymphoma and may have enhanced negative effect with MYC coexpression: a single institutional clinicopathologic study.
|
24619762 |
2014 |
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Radiotherapy seemed to diminish the prognostic effects of MYC rearrangements in diffuse large B-cell lymphoma patients since only 2/10 irradiated patients with MYC rearrangements died of/with disease, compared with 16/28 non-irradiated patients with MYC rearrangements.
|
24336156 |
2014 |
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
BCL2, BCL6, IGH, TP53, and MYC protein expression and gene rearrangements as prognostic markers in diffuse large B-cell lymphoma: a study of 44 Turkish patients.
|
24674866 |
2014 |